Respiratory Infections Rather Than Antibiotics May Increase Clozapine Levels: A Critical Review of the Literature

Sir: Approximately 70% of clozapine metabolism is explained by the cytochrome P450 1A2 (CYP1A2).1 The CYP1A2 can be inhibited by respiratory infections. Decreased theophylline (a CYP1A2 substrate) clearance during upper respiratory infections has been described in asthmatic children2,3 and in adults with chronic bronchitis.4 Cytokines released during infection decrease CYP1A2 activity and synthesis.5 Expert pediatricians recommend decreasing theophylline doses by half during severe respiratory infections.3

Two cases of increased plasma clozapine concentrations during respiratory infection were recently published.6,7 The English-language literature was reviewed in October 2003 with a PubMed search using all searchable years and several term combinations including clozapine and CYP3A, clozapine and macrolide, and clozapine and fluoroquinolone. All the references listed in the newly found articles and in those gathered over the course of my more than 7 years of interest in the subject were also reviewed to obtain all relevant articles. This critical review of the literature suggests that 3 prior clozapine toxicity cases attributed to drug interactions with erythromycin,6,8 or ampicillin9 are better explained by 1 pharyngitis case8 and 2 sinusitis cases.9,10 Ampicillin does not inhibit the CYPs.11 Erythromycin inhibits CYP3A, but a study of a single clozapine dose in 12 healthy males failed to show any effects of erythromycin.12 Similarly, itraconazole, another potent CYP3A inhibitor, did not influence clozapine metabolism.13 Therefore, in 2 patients taking erythromycin,8,9 CYP1A2 inhibition associated with a respiratory infection was probably the major factor contributing to clozapine toxicity, although some small effects of erythromycin cannot be ruled out. Assuming that clozapine follows linear pharmacokinetics,14 clozapine concentration-to-dose ratio associated with the respiratory infection decreased by a factor of 2 to 3 times (3.3, 2.0, 1.9, and 3.0).9

Clinicians caring for adult patients taking clozapine must therefore be careful should a patient develop serious respiratory infection with fever; they must pay particular attention to any signs suggesting clozapine toxicity (severe sedation, myoclonus, or even seizures). If any of these signs appear, the physician may need to decrease the clozapine dose, at least by half, until the patient has recovered from the infection. Obviously, this recommendation is limited by the small amount of published information supporting it (4 case reports); however, prospective studies in patients who are taking clozapine and having serious respiratory infections are unlikely to happen due to ethical and practical issues. The aim of this letter is to raise clinician awareness and stimulate the publication of new case report data that may or may not support the recommendation of decreasing the dose by half in clozapine-treated patients suffering a serious respiratory infection and showing signs of clozapine toxicity.

CYP1A2 also metabolizes olanzapine, an antipsychotic agent used more frequently than clozapine. The limited experience my colleague and I reported in 1 patient taking both clozapine and olanzapine suggests that olanzapine levels increased by a factor of 1.7 during severe respiratory infection. An increase by a factor of 2 (or 1.7) in olanzapine level may not have the same clinical implications as in clozapine levels; olanzapine has a much wider therapeutic window.

Finally, 3 clarifications are needed. (1) Not all antibiotics are free of drug interaction with clozapine; ciprofloxacin, a CYP1A2 inhibitor, can increase clozapine levels.15 (2) Smoking withdrawal for a few days during a respiratory infection may not have major effects on clozapine levels; the published case reports of clozapine toxicity after smoking cessation suggest that the increase of clozapine levels after smoking cessation usually takes at least 2 to 4 weeks to manifest.16 (3) Severe respiratory infections in patients taking clozapine can be associated with clozapine-induced agranulocytosis. According to data from the Clozaril National Registry, recent U.S. estimates suggest that agranulocytosis is less frequent (0.6%)17 than previously thought. Moreover, clozapine-induced agranulocytosis is very rare after 18 months of treatment18 and can be easily ruled out by drawing a white blood cell count.

The author received no financial support for writing this letter. In the past 2 years, he has been on the advisory board of Bristol-Myers Squibb and AstraZeneca, received researcher-initiated grants from Eli Lilly and Roche Molecular Systems, Inc, and gave a lecture supported by Eli Lilly.

REFERENCES
7. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1059–1063
10. Csik V, Molnar J. Possible adverse interaction between clozapine...
Letters to the Editor

and ampicillin in an adolescent with schizophrenia. J Child Adolesc
Psychopharmacol 1994;4:123–128
11. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions
erthyromycin and a single dose of clozapine. Eur J Clin Pharmacol
1999;55:221–226
13. Raaska K, Neuvonen PJ. Serum concentration of clozapine and N-desmethyloclozapine are unaffected by the potent CYP3A4
15. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine
and N-desmethyloclozapine: a study in patients with schizophrenia.
smoking cessation can lead to intoxication with clozapine or
olanzapine. Int Clin Psychopharmacol 2002;17:141–143
agranulocytosis: incidence and risk factors in the United States.

Jose de Leon, M.D.
University of Kentucky Mental Health Research Center at
Eastern State Hospital
Lexington, Kentucky

Psychotic Symptoms Associated With Topiramate:
Cognitive Side Effects or Worsening of Psychosis?

Sir: Hofer et al.1 report worsening of psychosis in a patient
treated with topiramate. There are anecdotal reports in the lit-
erature suggesting this adverse effect of topiramate. However,
the pathophysiologic mechanism cited by the authors to explain
this worsening of psychosis is contrary to what the literature
suggests. Inhibition of glutamate receptors is a hypothesized
cause of schizophrenia, but it is the hypofunction of the N-
methyol-α-aspartate (NMDA) receptor that has been implicated
in schizophrenia.2 Topiramate, on the other hand, is an antago-
ist at the α-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA)/kainate receptor. The latter action has been hy-
opthesized to reduce neuronal excitability and is used in the
treatment of seizure disorders.

One of the consequences of NMDA receptor hypofunction
in schizophrenia is the excessive and unregulated stimulation of
AMPA/kainate receptors, which in turn results in excitotoxic
damage; Deutsch and colleagues2 have explained this mecha-
nism in detail. On the basis of this hypothesis, topiramate
has been used to treat negative symptoms of schizophrenia.3
This use is further supported by a study4 which showed that to-
piramate attenuates a well-characterized behavior elicited by
MK-801, a phencyclidine analogue and an antagonist at the
NMDA receptor. Moreover, AMPA antagonists have been sug-
gested to possess an atypical antipsychotic profile.5 Therefore,
the mechanism of action of topiramate suggests that, rather than
causing worsening of psychosis, it has potential use in treating
at least some patients with schizophrenia.

Then how does one explain the presentation described by
Hofer and colleagues? Topiramate does cause cognitive side ef-
fects including word-finding difficulty, psychomotor slowing,
difficulty with concentration, somnolence, and fatigue. It has
also been shown to cause memory problems and exacerbation of
mood disturbance (e.g., irritability and depression).5 Some of
the symptoms cited as worsening of psychosis in the report may
be due to these cognitive side effects of topiramate. One patient
of ours (with a history of psychotic disorder) developed such

Dr. Hofer and Colleagues Reply

Sir: We appreciate the comments of Dr. Duggal regarding
our data concerning worsening of psychosis after replacement
of adjunctive valproate with topiramate in a patient with
schizophrenia. We agree completely with Dr. Duggal con-
cerning hypotheses suggesting that N-methyl-α-aspartate
(NMDA) receptor hypofunction, dampened γ-aminobutyric
acid (GABA)ergic inhibition, and excessive stimulation of the
kainic acid/α-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) class of glutamate receptors occur in at least
some patients with schizophrenia. Such a condition of “hypo-
glutamatergia” has been hypothesized to result in “paradoxical”
excessive stimulation of the kainic acid/AMPA receptors and
excitotoxicity, which in turn might explain the progressive
psychosocial and cognitive deterioration seen in a subgroup
of schizophrenia patients.1 Topiramate, a kainic acid/AMPA recep-
tor antagonist and GABA potentiator, has been suggested to be
an effective means of treating olanzapine-refractory schizo-
phrenia by decreasing negative symptoms. Positive symptoms
showed no changes in one patient2 and worsened in another.3 On
the other hand, piracetam, which acts an AMPA agonist, has

REFERENCES
1. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis
after replacement of adjunctive valproate with topiramate in a
2. Deutsch SI, Rosse RB, Schwarz BL, et al. A revised excitotoxic
hypothesis of schizophrenia: therapeutic implications. Clin
Neuropharmacol 2001;24:43–49
3. Drapalski AL, Rosse RB, Peebles RR, et al. Topiramate improves
deficit symptoms in a patient with schizophrenia when added to a
stable regimen of antipsychotic medication. Clin Neuropharmacol
2001;24:290–294
MK-801 in an animal model of schizophrenia. Eur J Pharmacol 2002;449:
121–125
5. Svensson TH. Dysfunctional brain dopamine systems induced by
psychotomimetic NMDA-receptor antagonists and the effects of
Medical Economics; 2003:2503

Harpreet S. Duggal, M.D., D.P.M.
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Dr. Hofer adds that the patient with schizophrenia and
the onset of irritability should be explored further to
determine if this was a coincidental event or part of
the treatment plan. The patient’s symptoms did not
improve with the addition of valproate, but the
symptoms did improve with the addition of risperidone.
Furthermore, the patient’s symptoms improved with
the addition of aripiprazole, which is an atypical
antipsychotic. This suggests that topiramate may
have an effect on the patient’s irritability, but
further investigation is needed to determine the
specific mechanisms involved.
also been suggested to be of therapeutic benefit in treating schizophrenia patients in combination with conventional antipsychotics. Therefore, it remains uncertain at present whether AMPA agonists, antagonists, or partial agonists/modulators should be pursued further in this indication.

Similar to our findings, Millson et al. have reported worsening of psychosis when topiramate was added to clozapine treatment in 3 schizophrenia patients. In addition, a psychiatric history has been described to be a potential risk factor for topiramate-related psychiatric adverse events in patients with epilepsy. The most common neuropsychiatric symptoms associated with topiramate include somnolence, dizziness, tiredness, ataxia, headache, depression, and cognitive impairment such as mental confusion, slow reasoning, speech difficulty, and disturbance of memory.

We agree with Duggal’s point that some of the symptoms cited as psychosis in our report might be confused with these cognitive side effects of topiramate. However, the patient in the reported case was diagnosed with acute psychotic disorder according to ICD-10 criteria, and his clinical features were similar to those he had shown when he experienced the first episode of the illness. The Positive and Negative Syndrome Scale was administered to quantify the degree of worsening of psychosis. There is no doubt that the patient developed a psychotic episode, which quickly remitted after topiramate treatment was discontinued and valproate treatment was resumed.

Dr. Fleischhacker has been a consultant for Janssen and Eli Lilly and has been a speakers/advisory board member for Janssen, Eli Lilly, Pfizer, Sanofi, and Bristol-Myers Squibb. Dr. Hamner has received grant/research support from Eli Lilly and has been a speakers/advisory board member for Janssen, Eli Lilly, Pfizer, and Bristol-Myers Squibb. Dr. Hofer reports no financial affiliation or other relationship relevant to the subject matter of this letter.

REFERENCES


Alex Hofer, M.D.
W. Wolfgang Fleischhacker, M.D.
Martina Hummer, M.D.
Department of Biological Psychiatry
Innsbruck University Clinics
Innsbruck, Austria

Successful Treatment of Sexual Dysfunction With Dronabinol: A Case Report

Sir: There have been numerous reports of the sexually enhancing effects of tetrahydrocannabinol (THC), and this letter reports positive outcome in a female bipolar patient after dronabinol use. Dronabinol, a medication currently labeled as Schedule III, is approved by the U.S. Food and Drug Administration (FDA) for treating nausea and increasing appetite. ∆9-tetrahydrocannabinol is the sole synthetic psychoactive ingredient of dronabinol. While dronabinol may still require the additional supervision needed for a controlled substance, because of its Schedule III classification in the controlled substances list of the Controlled Substances Act, the medication is not as restricted as a medication from the Schedule II list. In practical terms, dronabinol may be prescribed by telephone with up to 6 refills in a 6-month time period.

Case report. Ms. A, a 43-year-old married African American woman employed as a midlevel manager for a federally funded organization, had a history of bipolar disorder, mixed type (DSM-IV criteria), with numerous hospitalizations in the past 5 years for manic or depressive episodes that were always triggered by noncompliance with her medications. After her last relapse, she had readily admitted that the single most important factor in her noncompliance was sexual dysfunction secondary to her psychotropic medications (olanzapine, valproic acid, and paroxetine). In the past, bupropion, methylphenidate, and yohimbine had been tried, but the patient had experienced no relief from her major complaint of anorgasmia. She had no history of substance abuse.

In November 2001, Ms. A was instructed to use dronabinol 10 mg p.r.n. 1 hour before sex. She was advised that she should not drive a vehicle for 24 hours after using dronabinol and that she should not resume her job.

An interesting and potentially serious complication occurred during the course of treatment. In routinely administered testing at her workplace, Ms. A tested positive for THC and was immediately suspended from work, but, fortunately, after a second opinion from a university-based colleague and a medical report from me addressing the rationale for her pharmacotherapy, the medical director of her company ruled in her favor, and she resumed her job.

Dronabinol’s potential for producing sexually enhancing effects that reverse psychotropic-induced sexual dysfunction is probably multifactorial. Dronabinol causes euphoria and relaxation, and because these emotional states may promote sexual pleasure, it is likely that the positive sexual response is due in part to this very avenue. Most likely, there are other unknown mechanisms involved in dronabinol’s sexually enhancing effects. Particular attention must be paid to patients with bipolar disorder due to the greater risk of substance abuse among bi-
Letters to the Editor

Dr. Salerian has served as a consultant for and received honoraria from Eli Lilly, Pfizer, Janssen, Wyeth-Ayerst, SmithKline Beecham, and Shire.

REFERENCES


Alen J. Salerian, M.D.
Washington Center for Psychiatry
Washington, D.C.

Withdrawal Reactions Associated With Low-Dose Venlafaxine Treatment in a Patient With Premenstrual Dysphoric Disorder

SIR: It has recently been demonstrated that venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is effective for the treatment of premenstrual dysphoric disorder (PMDD). However, withdrawal reactions with venlafaxine have been reported. Most of these withdrawal reactions were noted in patients with depressive disorder and associated with daily venlafaxine doses of 150 mg or more. We describe the development of withdrawal symptoms after discontinuation of low-dose venlafaxine treatment in a patient with PMDD.

Case report. Ms. A, a 25-year-old single woman, visited our premenstrual syndrome (PMS) clinic in February 2003 due to premenstrual mood problems that had persisted for 2 years. She met the DSM-IV research criteria for a diagnosis of PMDD. After a series of laboratory tests and prospective daily recording of symptoms with the 35-item Prospective Record of the Impact of Symptoms (PRISM) calendar for 2 menstrual cycles, the diagnosis of PMDD was confirmed. No other psychiatric diagnosis was noted, and the patient described no family history of mental illness.

Ms. A was treated with venlafaxine 18.75 mg/day for the first 5 days, then the dosage was titrated to 37.5 mg/day for the rest of the treatment course. The patient’s PMDD symptoms were much improved during the first cycle. The PRISM calendar revealed more than 70% improvement in late–luteal-phase dysphoria. Comparison of the patient’s pretreatment and post-treatment premenstrual condition revealed that her Hamilton Rating Scale for Anxiety score dropped from 16 to 4, while her Hamilton Rating Scale for Depression score dropped from 13 to 3. Ms. A’s Clinical Global Impressions–Severity of Illness scale score decreased from 5 (markedly ill) to 1 (not at all ill), and her Clinical Global Impressions–Improvement scale score was 1 (very much improved) in the second cycle after beginning treatment.

Unfortunately, after 2 months of effective treatment with low-dose venlafaxine, Ms. A missed taking a single 37.5-mg venlafaxine tablet one night. The apparent withdrawal reactions developed 14 hours after the missed dose. Clinical manifestations included disequilibrium features (dizziness, vertigo, ataxia), gastrointestinal symptoms (nausea, irritation), sensory disturbances (paresthesia, shocklike sensations), and sleep and psychological symptoms (anxiety, jitteriness, insomnia). The patient could not work and had to rest in bed for the next 2 days. She refused to take the agent again and did not seek any medical help. The withdrawal reactions progressively disappeared over the next 4 days.

Although the possibility of a withdrawal reaction is mentioned in the manufacturer’s data sheet, the implication is that such reactions are observed with daily doses of 150 mg or more. An important issue that should be addressed is the occurrence of withdrawal reactions with even such low doses of venlafaxine as the one in the present case.

Newer antidepressants for PMDD have acute-phase efficacy, and recent preliminary studies have also revealed similar efficacy with intermittent doses of selective serotonin reuptake inhibitors in the symptomatic premenstrual phase in comparison to full-cycle treatment. Given this fluctuating, phase-dependent sensitivity to antidepressants, antidepressant withdrawal reactions become an important consideration in the treatment of PMDD.

It seems reasonable to suggest that clinicians be aware of the risk of withdrawal reactions for novel antidepressants, especially venlafaxine, during both intermittent and long-term treatment of PMS/PMDD patients.

Supported by grant NSC-90-2314-B-182-054 from the National Science Council, Taipei, Taiwan, and grant CMRP-1267 from Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Dr. Liu has received grant/research support from Eli Lilly, Wyeth, and GlaxoSmithKline and has participated in speakers/advisory boards for GlaxoSmithKline, Wyeth, and Pfizer.

REFERENCES

Letters to the Editor

Mei-Chun Hsiao, M.D.
Chia-Yih Liu, M.D.
Department of Psychiatry
Chang Gung Memorial Hospital and
Chang Gung University School of Medicine
Taoyuan, Taiwan

Measuring Efficacy of Polypharmacy in Schizophrenic Inpatients

Sir: McCue et al.1 compare a number of indirect parameters assessing the effectiveness of polypharmacy in the treatment of acutely ill inpatients with schizophrenia. While we all welcome data that would support the safety and rationality of polypharmacy in schizophrenia treatment, the data the authors present are difficult to interpret. Their study carries some methodological flaws and uses a number of indirect parameters that most likely have alternative explanations.

The authors compared 459 and 584 inpatients discharged in 2 different years. They indicate that in each group some patients had several discharges in the same year; presumably, they chose only 1 discharge for such patients, as their final number of subjects is smaller than the number of discharged patients for the particular year. By what criteria did they choose the particular discharge data of a multiply discharged patient, and were the criteria applied in the same manner in the 2 time periods under investigation?

Two parameters were chosen as proxy measures of the effectiveness of polypharmacy: the length of stay and the discharge rates to state facilities. Both of these parameters are more likely to reflect outside, nonpharmacologic factors, such as administrative hospital pressures on length of stay. In fact, the Office of Mental Health, which regulates the rates of transfers to long-term state facilities in the state of New York, significantly decreased the flow of transfers to its facilities between the 2 timepoints under investigation, making this particular measure clinically useless.2 Furthermore, comparing the number of adverse events between the 2 time periods is not very meaningful, as the reported rates in the 2 cohorts are unusually low (18 vs. 6).

The heuristically safe and limited conclusion of the authors’ data is to state that polypharmacy in acute inpatients with schizophrenia was increased in 2000 as compared with 1995.

REFERENCES


Jean-Pierre Lindenmayer, M.D.
Manhattan Psychiatric Center
Psychopharmacology Research Unit
New York University
New York, New York

Dr. McCue and Colleagues Reply

Sir: We welcome all comments on our report, the methodological limitations and tentative conclusions of which are outlined in the Discussion section of the article. A more careful reading of the Method section by Dr. Lindenmayer would have addressed his concern about our using only 1 admission of patients with multiple admissions. In fact, we used all discharges with the diagnosis of schizophrenia in 1995 and 2000. The number of unique patients in these samples was noted in the article.

It is true that the number of admissions to state facilities decreased between 1995 and 2000 because of a concerted effort by the state of New York to reduce the number of beds. However, this decrease did not affect the number of patients in need of intermediate- or long-term care, but only the availability of beds in state facilities for these patients. As a result, if fewer patients in need of intermediate- or long-term care were transferred to state facilities in 2000, then they would have remained hospitalized at our acute service until ready for discharge. Length of stay at our facility would have increased if all else remained the same. In fact, our patients with schizophrenia had a reduced length of stay in 2000, even with the reduced availability of state hospital beds. Other factors affected our patients’ readiness for discharge: the change we found in prescription practices may be one of them.

In addition, there was a significant reduction in adverse drug reactions between 1995 and 2000 that was very likely attributable to fewer extrapyramidal effects because of the increased use of atypical antipsychotics. We leave it to the reader, including Dr. Lindenmayer, to decide whether this reduction is meaningful. We thought it was.

We appreciate Dr. Lindenmayer’s restatement of our primary conclusion that polypharmacy increased in acute patients with schizophrenia between 1995 and 2000. We believe that our other observations about fewer adverse drug reactions and improved patient outcome require stronger counter-arguments before being dismissed.

The authors report no financial affiliation or other relationship relevant to the subject matter of this letter.

Robert E. McCue, M.D.
Rubina Waheed, M.D.
Leonel Urcuyo, M.D.
Department of Psychiatry
Woodhull Medical and Mental Health Center
Brooklyn, New York
Development of Guidelines for Preventing and Managing Obesity and Diabetes in Mentally Ill Patients

Sir: I would like to thank you for publishing in *The Journal of Clinical Psychiatry* the proceedings from the consensus development conference held in November 2003 between the American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Though originally published in *Diabetes Care,* publication in the psychiatric literature ensures that the proceedings are viewed by the majority of psychiatrists and mental health clinicians who are the primary prescribers of antipsychotics, including the second-generation agents.

Obesity is a significant national health concern and cannot be divorced from type 2 diabetes mellitus. The monitoring protocol suggested in the proceedings is impressive and will help detect metabolic syndrome early. Increased waist circumference and elevated diastolic blood pressure are good early clinical indicators of metabolic syndrome. In our outpatient practice, we have been monitoring fasting glucose and lipid profiles in the chronically mentally ill for over 2 years (including those not treated with second-generation agents) and have found that we are detecting younger individuals with diabetes and dyslipidemia. In light of this discovery, we have instituted establishment of a fasting lipid profile for inpatients, including those admitted to our child and adolescent unit.

We have been measuring patients’ abdominal girth (at the level of the umbilicus) in addition to weight, pulse, and blood pressure in one of the day treatment programs for approximately 1 year. Abdominal girth measurement has turned out to be an intervention, as patients begin to inquire about the reason for measurement and subsequently want to know what they could do to reduce their waist size. We have specifically suggested replacing soft drinks with water (some patients drink up to 4 L/day; liquid carbohydrate content can approach close to 600 g) and walking 30 minutes per day.

Finally, we are instituting these guidelines so that more patients will be screened and diabetes and lipid disorders (whether due to second-generation agents or to other factors) will be detected earlier, to hopefully prevent patients from developing ketoacidosis. We also suggest that patients presenting with vague complaints, especially visual ones, should have a random blood glucose test (high levels of unstable sugars cause visual changes). It appears that the evidence is mounting that chronic psychiatric illnesses (e.g., schizophrenia and bipolar disorder) should be considered as independent risk factors for type 2 diabetes mellitus, and the consensus conference should also have made a statement on this issue.

The authors report no financial affiliation or other relationship relevant to the subject matter of this letter.

**REFERENCES**


Sanjay Gupta, M.D.
Bradford L. Frank, M.D., M.P.H., M.B.A.
Department of Psychiatry
University of Buffalo School of Medicine and Biomedical Sciences
Buffalo, New York

Effect of Mirtazapine Versus Fluoxetine on “Sleep Quality”

Sir: As a psychiatrist in clinical practice, I appreciate the importance of restoring sleep quality in my depressed patients. I therefore read with interest the recent article by Winokur et al., comparing the sleep physiology effects of mirtazapine versus fluoxetine. Unfortunately, the authors seemed to demonstrate only that a drug with a sedative side effect causes more drowsiness than a drug without it.

In the study, mirtazapine not surprisingly helped depressed patients fall asleep more quickly and stay asleep longer. In other words, the patients showed a decrease in sleep latency, increased total sleep time, and thus improved sleep efficiency throughout the 8 weeks. The fact that most of these changes were statistically significant as early as week 1 seems merely to reflect mirtazapine’s well-known sedative side effect; there was no basis for linking this effect to the more slowly developing improvement in sleep quality associated with antidepressant benefit. Indeed, the authors liken sleep alterations with mirtazapine to those produced by the hypnotic compounds zolpidem and zaleplon, two drugs with no claim to antidepressant efficacy.

Moreover, the study seems to draw an unfair comparison, since the doses of the two drugs were not comparable. While 45 mg of mirtazapine at bedtime is appropriate, the fluoxetine subjects were moved up to 40 mg daily—twice what the package insert states is sufficient for most patients and, in my opinion, actually 4 times what is usually necessary. With this excessive dose comes increased risk for at least 2 adverse effects that can unfavorably impact the parameters of this study. Subjects who experience activation with fluoxetine will, of course, have greater trouble falling asleep at bedtime. On the other hand, there are some individuals who feel somnolence with a fluoxetine dose this high; presumably, they will be more inclined to take daytime naps (apparently not prohibited in the study), and this, in turn, could prolong sleep latency at bedtime. The incidence of these two side effects, excessive activation and daytime somnolence, was not noted.

Bearing out these concerns, the authors’ data indicate that sleep latency in the fluoxetine group was actually slightly improved at week 1, when the dose was 20 mg and there had not yet been much accumulation of this slowly metabolized drug. It is only after week 8 that we see worsening in sleep latency, reflecting the high drug levels accumulated during 4 weeks of taking a daily dose of 40 mg.

The authors make several references to the fluoxetine-associated increases in stage 1 sleep, “generally interpreted as a disruption of sleep continuity.” However, there is no explanation for, or even mention of, the considerable disparity between the baseline amounts of stage 1 sleep: 38.7 minutes for the fluoxetine group and 66.2 minutes for mirtazapine subjects. Further, while stage 1 sleep climbed to a mean of 67.9 minutes by week 8 on fluoxetine treatment, the amount of stage 1 sleep eventually achieved by the mirtazapine subjects was a remarkable 111.2 minutes. In other words, stage 1 sleep increased by 75.4% with fluoxetine and 68.0% with mirtazapine. I will take the authors’ word that the former increase was statistically significant while the latter was not, but spending almost 2 hours per night in stage 1 does not speak to a great sleep benefit from mirtazapine.

The authors conclude, “These alterations in sleep physiology [with mirtazapine] are indicative of improvement in sleep quality.” However, this statement begs the question of what is truly meant by the concept of “sleep quality” when we
Possible Impact of Dropout in a Study of High-Dose Olanzapine and Prolactin Levels

Sir: Prolactin elevation as a consequence of antipsychotic drug therapy may result in decreased sexual desire, difficulties in sexual performance, and gynecomastia in men and in amenorrhea, infertility, breast engorgement, and lactation in women.1 Karagianis and Baksh 2 studied 24 patients to determine whether high-dose (20–40 mg/day) olanzapine was associated with prolactin elevation. They found that there was no correlation between dose of olanzapine and prolactin level, that the highest elevation of prolactin was 20 ng/mL, and that only 21% of patients had (mildly) elevated prolactin levels. They concluded that prolactin elevation may not be a significant problem with olanzapine at the doses studied.

Karagianis and Baksh2 admitted several limitations to their study. However, they did not note that the most serious limitation was that the mean duration of olanzapine therapy was 15.3 months, which raises the possibility that patients who experienced prolactin-related problems may have dropped out of treatment and may thereby have been preselected out of the sample. Therefore, conclusions about the effect of high-dose olanzapine on prolactin levels must remain guarded.

Dr. Andrade reports no financial affiliation or other relationship relevant to the subject matter of this letter.

REFERENCES


Chittaranjan Andrade, M.D.
Department of Psychopharmacology
National Institute of Mental Health and Neurosciences
Bangalore, India

Drs. Karagianis and Baksh Reply

Sir: While we agree that dropouts could potentially influence this type of study, in this particular study they did not. All patients were from the senior author’s (J.L.K.’s) clinical practice, and no patient meeting the inclusion criteria dropped out. All patients had to be taking at least 20 mg/day of olanzapine for at least 4 months. Furthermore, any patient who would have dropped out prior to meeting inclusion criteria could not have been considered to be on high-dose, long-term treatment. This study was not intended to address the issue of prolactin elevation after low-dose or short-term treatment with olanzapine. Among all of the senior author’s olanzapine patients (hundreds), only 2 have ever stopped olanzapine treatment due to side effects related to prolactin elevation, and these patients were receiving low-dose, short-term therapy.

Dr. Karagianis is now an employee of Eli Lilly Canada; however, neither the original article nor this letter was supported by Eli Lilly.

Dr. Baksh reports no financial affiliation or other relationship relevant to the subject matter of this letter.

James L. Karagianis, M.D., F.R.C.P.C.
Anton Baksh, M.D., F.R.C.P.C.
Faculty of Medicine
Memorial University of Newfoundland
St. John’s, Newfoundland, Canada

Correction

In the article “Health-Related Quality of Life in Patients With Schizophrenia During Treatment With Long-Acting, Injectable Risperidone” by Henry A. Nasrallah, M.D., et al. (April 2004 issue, pp. 531–536), the population of the placebo group in Figure 3B on page 534 should be 28.